AKBA Stock Recent News
AKBA LATEST HEADLINES
Akebia gained approval for Vafseo, its anemia therapy for chronic kidney disease patients, in Great Britain. The company is awaiting word on its appeal to the FDA to get approval for the therapy in the U.S. In May, Akebia said it has $57 million, enough cash to fund operations for another 12 months.
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q1 2023 Earnings Conference Call May 8, 2023 8:30 AM ET Company Participants Mercedes Carrasco - Senior Director of Investor and Corporate Communications John Butler - Chief Executive Officer Dave Spellman - Chief Financial Officer Conference Call Participants Allison Bratzel - Piper Sandler Thomas Yip - H.C. Wainwright Operator Good day, and thank you for standing by.
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.35 per share a year ago.
Analysts say these could be penny stocks to buy. Do you agree with their outlook?
Penny stocks under $1 to watch right now. The post 10 Hot Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 71.43% and 14.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Penny stocks under $1 to watch this week. The post 7 Hot Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Penny stocks insiders are selling? What the details suggest.
GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.
Penny stocks to watch before next year. The post Best Penny Stocks To Buy?